Opgen INC

CapForce Inc., formerly OpGen, Inc., announced stockholder approval of its new corporate name, a 2026 Incentive Compensation Plan, and key corporate governance matters, signaling a strategic pivot to fintech-enabled investment banking.

OpGen, Inc. has completed the acquisition of Sun Investment Enterprises Limited, gaining full ownership of fintech platform iCapX Sdn. Bhd. for $12.3 million paid in common stock, and secured an estimated $14 million advisory fee from a client.

OpGen, Inc. announced an extension of its equity financing agreement with AEI Capital Ltd. until December 31, 2026, alongside the resignation of President David Lazar effective January 8, 2026.

OpGen, Inc. announced the appointment of Christian-Laurent Bonte as its new Chief Executive Officer, succeeding John Tan Honjian who will continue as Chairman of the Board.

OpGen, Inc. announced the resignation of director Christian-Laurent Benoit Bonte, who will transition to lead the Digital Investment Banking Arm of its wholly-owned subsidiary, CapForce International Holdings Ltd.

OpGen, Inc. is strategically repositioning itself into the digital investment banking industry through its wholly-owned subsidiary, CapForce International Holdings Ltd., which has acquired an IPO advisory mandate and formed a joint venture with European Credit Investment Bank.

OpGen, Inc. has completed its strategic pivot from precision medicine to financial services and technology, reporting significant revenue from new listing sponsorship services.

OpGen, Inc. reported a significant turnaround to profitability in Q2 2025, driven by its strategic pivot to financial services and technology, despite its recent delisting from Nasdaq.

OpGen, Inc. reported a net loss of $0.4 million in Q1 2025, a significant shift from profit, as it fully transitioned from precision medicine to financial services and technology, with no revenue generated from legacy operations.

OpGen Inc. reports a significant net income for Q3 2024 driven by debt extinguishment and strategic repositioning, while legacy operations wind down.

OpGen Inc. reported its second quarter 2024 results, reflecting a significant decrease in revenue and operating expenses due to the insolvency of its subsidiaries and a strategic shift towards a potential sale or reverse merger.

OpGen, Inc. has filed an amended quarterly report to restate its Q1 2024 financials due to an accounting error related to a lease indemnification asset, resulting in a net income of $0.3 million.

CapForce Inc. has reported a significant increase in revenue for the fiscal year ended December 31, 2025, driven by its listing sponsorship services.

OpGen, Inc. has undergone a significant strategic shift from precision medicine to financial technology, reporting a 52% increase in total revenue for 2024 driven by new listing sponsorship services.

OpGen Inc. reports its 2023 financial results and outlines a strategic shift towards identifying a reverse merger target after its subsidiaries filed for insolvency.

CapForce Inc. Director Victor Chua acquired 5,555 shares of common stock through a restricted stock unit award.

CapForce Inc. COO, Azudin Mohd Azham, was granted 5,555 restricted stock units on February 23, 2026, with full vesting on December 3, 2026, or upon a change in control.

Director Lim Zhao Qi Ken acquired 5,555 restricted stock units from CapForce Inc. on February 23, 2026.

CapForce Inc. reports an award of 2,778 restricted stock units to Corporate Secretary Gillian Tan Rou Yee, with vesting tied to time or a change in control.

CapForce Inc. director Ethan Low acquired 5,555 shares of common stock through a restricted stock unit award.

CapForce Inc. director Constance Wong acquired 5,555 shares of common stock through an award of restricted stock units.

OpGen, Inc. is seeking stockholder approval for a strategic name change to CapForce Inc., reflecting its pivot to digital investment banking, alongside a new equity incentive plan and warrant exercises.

OpGen is convening a special meeting of stockholders to vote on proposals including a share issuance to David Lazar, a reverse stock split, and adjournment if necessary.